LW-213 induces cell apoptosis in human cutaneous T-cell lymphomas by activating PERK-eIF2α-ATF4-CHOP axis

Acta Pharmacol Sin. 2021 Feb;42(2):290-300. doi: 10.1038/s41401-020-0466-7. Epub 2020 Aug 3.

Abstract

Cutaneous T-cell lymphoma (CTCL) is characterized by a heterogeneous group of extranodal non-Hodgkin lymphomas, in which monoclonal T lymphocytes infiltrate the skin. LW-213, a derivative of wogonin, was found to induce cell apoptosis in chronic myeloid leukemia (CML). In this study, we investigated the effects of LW-213 on CTCL cells and the underlying mechanisms. We showed that LW-213 (1-25 μM) dose-dependently inhibited human CTCL cell lines (Hut-102, Hut-78, MyLa, and HH) with IC50 values of around 10 μM, meanwhile it potently inhibited primary leukemia cells derived from peripheral blood of T-cell lymphoma patients. We revealed that LW-213-induced apoptosis was accompanied by ROS formation and the release of calcium from endoplasmic reticulum (ER) through IP3R-1channel. LW-213 selectively activated CHOP and induced apoptosis in Hut-102 cells via activating PERK-eIF2α-ATF4 pathway. Interestingly, the degree of apoptosis and expression of ER stress-related proteins were alleviated in the presence of either N-acetyl cysteine (NAC), an ROS scavenger, or 2-aminoethyl diphenylborinate (2-APB), an IP3R-1 inhibitor, implicating ROS/calcium-dependent ER stress in LW-213-induced apoptosis. In NOD/SCID mice bearing Hut-102 cell line xenografts, administration of LW-213 (10 mg/kg, ip, every other day for 4 weeks) markedly inhibited the growth of Hut-102 derived xenografts and prolonged survival. In conclusion, our study provides a new insight into the mechanism of LW-213-induced apoptosis, suggesting the potential of LW-213 as a promising agent against CTCL.

Keywords: 2-APB; CTCL; ER stress; LW-213; NAC; ROS; apoptosis; calcium; flavonoids; wogonin.

MeSH terms

  • Activating Transcription Factor 4 / metabolism
  • Animals
  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / pharmacology*
  • Apoptosis / drug effects
  • Cell Line, Tumor
  • Dose-Response Relationship, Drug
  • Eukaryotic Initiation Factor-2 / metabolism
  • Female
  • Flavanones / administration & dosage
  • Flavanones / chemistry
  • Flavanones / pharmacology*
  • Humans
  • Inhibitory Concentration 50
  • Lymphoma, T-Cell, Cutaneous / drug therapy*
  • Lymphoma, T-Cell, Cutaneous / pathology
  • Mice
  • Mice, Inbred NOD
  • Mice, SCID
  • Reactive Oxygen Species / metabolism
  • Skin Neoplasms / drug therapy*
  • Skin Neoplasms / pathology
  • Transcription Factor CHOP / metabolism
  • Xenograft Model Antitumor Assays
  • eIF-2 Kinase / metabolism

Substances

  • ATF4 protein, human
  • Antineoplastic Agents
  • DDIT3 protein, human
  • Eukaryotic Initiation Factor-2
  • Flavanones
  • Reactive Oxygen Species
  • Activating Transcription Factor 4
  • Transcription Factor CHOP
  • EIF2AK3 protein, human
  • eIF-2 Kinase
  • wogonin